Neurol. praxi. 2022;23(3):239-244 | DOI: 10.36290/neu.2022.032

Improving gait in patients with multiple sclerosis

Mgr. Klára Novotná, Ph.D.1, 2, 3, MUDr. Jana Lízrová Preiningerová1
1 Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze
2 Klinika rehabilitačního lékařství 1. LF UK a VFN v Praze
3 MSrehab, z. s., Praha

Gait impairment is among the most limiting symptoms in multiple sclerosis. The goal of specific treatment with immunomodulatory drugs (disease-modifying drugs, DMD) is to halt or at least suppress disease activity as much as possible. Despite this, gait impairment may occur in some patients. In such a case, it is possible to offer symptomatic pharmacological treatment or rehabilitation therapy. Symptomatic drugs intended to treat gait impairment particularly include the medicinal product fampridine (Fampyra®) which has been available in the Czech Republic since 2011. In April 2022, it became possible to receive reimbursement by health insurance for this drug; as a result, attending physicians may now be more likely to encounter requests for prescribing this preparation. The article aims to summarize possible benefits of this drug and describe specific conditions of reimbursement. Also discussed are the options of rehabilitation therapy for gait impairment.

Keywords: multiple sclerosis, gait, fampridine, rehabilitation.

Received: May 24, 2022; Revised: May 24, 2022; Accepted: May 29, 2022; Prepublished online: May 29, 2022; Published: June 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotná K, Lízrová Preiningerová J. Improving gait in patients with multiple sclerosis. Neurol. praxi. 2022;23(3):239-244. doi: 10.36290/neu.2022.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allart E, Benoit A, Blanchard-Dauphin B, et al. Sustained­‑released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262(8):1936-1945. Go to original source... Go to PubMed...
    2. Bakirtzis C, Konstantinopoulou E, Langdon DW, et al. Long­‑term effects of prolonged­‑release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. J Neurol Sci. 2018;395:106-112. Go to original source... Go to PubMed...
    3. Cameron MH, Wagner JM. Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep. 2011;11(5):507-515. Go to original source... Go to PubMed...
    4. Filli L, Zörner B, Kapitza S, et al. Monitoring long­‑term efficacy of fampridine in gait­‑impaired patients with multiple sclerosis. Neurology. 2017;88(9):832-841. Go to original source... Go to PubMed...
    5. Fischer J, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Multiple Sclerosis Journal. 1999;5(4):244-250. Go to original source... Go to PubMed...
    6. Fox EE, Hough AD, Creanor S, et al. Effects of Pilates­‑Based Core Stability Training in Ambulant People With Multiple Sclerosis: Multicenter, Assessor­‑Blinded, Randomized Controlled Trial. Phys Ther. 2016;96(8):1170-1178. Go to original source... Go to PubMed...
    7. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-333. Go to original source... Go to PubMed...
    8. Goldman MD, Motl RW, Seagnelli J, et al. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013;81(21):1856-1863. Go to original source... Go to PubMed...
    9. Goldman MD, Cohen JA, Cross A, et al. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Multiple Sclerosis Journal. 2017;23(10):1405-1414. Go to original source... Go to PubMed...
    10. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494-502. Go to original source... Go to PubMed...
    11. Goodman AD, Brown TR, Krupp LB, et al. Sustained­‑release oral fampridine in multiple sclerosis: a randomised, double­‑blind, controlled trial. The Lancet. 2009;373(9665):732-738. Go to original source... Go to PubMed...
    12. Goodman AD, Cohen JA, Cross A, et al. Fampridine­‑SR in multiple sclerosis: a randomized, double­‑blind, placebo­‑controlled, dose­‑ranging study. Multiple Sclerosis Journal. 2007;13(3):357-368. Go to original source... Go to PubMed...
    13. Henney III HR, Faust B, et al. Effect of food on the single­‑dose pharmacokinetics and tolerability of dalfampridine extended­‑release tablets in healthy volunteers. American Journal of Health­‑System Pharmacy. 2011;68(22):2148-2154. Go to original source... Go to PubMed...
    14. Hobart J, Blight A, Goodman A, et al. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509-1517. Go to original source... Go to PubMed...
    15. Hobart J, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2013;60(1):31-36. Go to original source... Go to PubMed...
    16. Horton L, Conger A, Conger D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology. 2013;80(20):1862-1866. Go to original source... Go to PubMed...
    17. Hoskovcová MM, Gál O. Problematika spastické parézy u pacientů s roztroušenou sklerózou. Neurol. praxi. 2018;17(Suppl. 4: Současné trendy v rehabilitaci pacientů s RS): 15-19.
    18. Jensen HB, Ravnborg M, Mamoei S, et al. Changes in cognition, arm function and lower body function after slow­‑release Fampridine treatment. Multiple Sclerosis Journal. 2014;20(14):1872-1880. Go to original source... Go to PubMed...
    19. Kalron A, Aloni R. Contrasting relationship between depression, quantitative gait characteristics and self­‑report walking difficulties in people with multiple sclerosis. Mult Scler Relat Disord. 2018;19:1-5. Go to original source... Go to PubMed...
    20. Kaufman M, Moyer D, Norton J, et al. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6(4):286-290. Go to original source... Go to PubMed...
    21. Kjølhede T, Vissing K, Dalgas U, et al. Multiple sclerosis and progressive resistance training: a systematic review. Multiple Sclerosis Journal. 2012;18(9):1215-1228. Go to original source... Go to PubMed...
    22. Kolčava J, Sládečková M, Kočica J, et al. Validace dotazníku pro poruchy chůze u pacientů s roztroušenou sklerózou - česká verze MSWS-12; 2021.
    23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1883;33(11):1444. Go to original source... Go to PubMed...
    24. Magnin E, Sagawa Y, Chamard L, et al. Verbal fluencies and fampridine treatment in multiple sclerosis. Eur Neurol. 2015;74(5-6):243-250. Go to original source... Go to PubMed...
    25. McDonald S, Clements JN. Dalfampridine: a new agent for symptomatic management of multiple sclerosis. American Journal of Health­‑System Pharmacy. 2011;68(24): 2335-2340. Go to original source... Go to PubMed...
    26. Mehta L, McNeil M, Hobart J, et al. Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. Multiple Sclerosis Journal-Experimental, Translational and Clinical. 2015;1:2055217315596993. Go to original source... Go to PubMed...
    27. Miller L, McFadyen A, Lord CA, et al. Functional electrical stimulation for foot drop in multiple sclerosis: a systematic review and meta­‑analysis of the effect on gait speed. Arch Phys Med Rehabil. 2017;98(7):1435-1452. Go to original source... Go to PubMed...
    28. Morris ME, Cantwell C, Vowels L, et al. Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2002;72(3):361-365. Go to original source... Go to PubMed...
    29. Motl RW, Cohen AJ, Benedict R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5): 704-710. Go to original source... Go to PubMed...
    30. Novotna K, Lízrová J, Sobisek L, et al. What Variability of Treatment Effect of Fampridine Can We Expect in People with Multiple Sclerosis? Journal of Multiple Sclerosis. 2017;4(3):1-5. Go to original source...
    31. Pavsic K, Pelicon K, Ledinek AH, et al. Short­‑term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clinical neurology and neurosurgery. 2015;139:35-40. Go to original source... Go to PubMed...
    32. Valet M, Quoilin M, Lejeune T, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta­‑analysis. CNS drugs. 2019;33(11):1087-1099. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.